Eli Lilly Buys AtaiBeckley for Up to $3.8 Billion as Psychedelic Drug Bets Accelerate
Updated
Updated · CNBC · Jul 19
Eli Lilly Buys AtaiBeckley for Up to $3.8 Billion as Psychedelic Drug Bets Accelerate
3 articles · Updated · CNBC · Jul 19
Summary
$3.8 billion is Lilly’s maximum price for AtaiBeckley, giving the drugmaker a late-stage psychedelic pipeline led by BPL-003 for treatment-resistant depression.
BPL-003—an intranasal synthetic 5-MeO-DMT therapy—has FDA Breakthrough Therapy status, is in Phase 3 trials, and could open a $1 billion to $2 billion market if it succeeds by early 2029, Jefferies said.
The deal lands as psychedelic medicines gain momentum from positive trial readouts, including strong recent Phase 3 data for LSD- and psilocybin-based depression treatments, and from Trump’s April order to speed FDA reviews.
Big Pharma has already started buying in: Otsuka acquired Transcend for $1.2 billion in June and AbbVie bought a Gilgamesh compound last year for $1.2 billion.
J&J’s Spravato offers a commercial template—sales rose 40% to $584 million last quarter—while the broader psychedelic drug market is projected to grow from $4.63 billion in 2026 to $8.75 billion by 2031.
With billion-dollar price tags, will new psychedelic cures be a luxury for the few or accessible to all?
Is the race for psychedelic drugs a mental health revolution or the start of a new public health crisis?
Eli Lilly Acquires AtaiBeckley for $3.8B, Signaling Big Pharma’s Leap Into Psychedelic-Based Mental Health
Overview
Eli Lilly’s announcement to acquire AtaiBeckley marks a major turning point in mental health treatment, as it brings a leading pharmaceutical company into the fast-growing field of psychedelic-based therapies. This move reflects the increasing scientific and regulatory support for psychedelics and is expected to reshape both mental health care and pharmaceutical investment. The news triggered a dramatic surge in AtaiBeckley’s shares, highlighting strong investor confidence in the potential of these therapies. Lilly’s entry signals a new era for the industry, where innovative treatments for challenging conditions are gaining mainstream attention and support.